{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"241.2","value":"420.3"},{"groupId":"OG001","spread":"75","value":"515"},{"groupId":"OG002","spread":"1267.39","value":"704.74"},{"groupId":"OG003","spread":"66","value":"1430"},{"groupId":"OG004","spread":"19","value":"775"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"description":"PK: Maximum concentration of LY3009120 during a twice daily dosing interval at steady state, Cycle 1 Day 15.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"50 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.","id":"OG000","title":"50 mg LY3009120"},{"description":"100 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.","id":"OG001","title":"100 mg LY3009120"},{"description":"200 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.","id":"OG002","title":"200 mg LY3009120"},{"description":"300 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.","id":"OG003","title":"300 mg LY3009120"},{"description":"400 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.","id":"OG004","title":"400 mg LY3009120"},{"description":"500 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.","id":"OG005","title":"500 mg LY3009120"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants in Part A who received at least one dose of study drug and have evaluable PK data for Cycle 1, Day 15, per protocol.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10 h post-dose","title":"Pharmacokinetics (PK): Maximum Concentration (Cmax) at Steady State of LY3009120 Cycle 1 Day 15","type":"SECONDARY","unitOfMeasure":"ng/mL"}